Abstract:Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the first choice for first-line treatment of advanced patients with EGFR positive non-small cell lung cancer (NSCLC). For advanced NSCLC patients with negative drive gene and positive programmed cell death ligand 1 (PD-L1) or highly expressed NSCLC patients, the first-line treatment recommends immune checkpoint inhibitors (ICIs) monotherapy or ICIs combined chemotherapy. Therefore, the first-line treatment strategy for advanced NSCLC patients with EGFR positive at different PD-L1 expression levels is worth further exploring. Many previous studies have suggested that the expression of PD-L1 is obviously affected by EGFR mutation, and the expression of PD-L1 is likely to be related to the mechanism of EGFR-TKIs resistance. The purpose of this study was to analyze the expression characteristics of PD-L1 in patients with advanced EGFR positive NSCLC and its relationship with the efficacy of EGFR-TKIs. Methods: 159 patients with newly diagnosed advanced NSCLC with EGFR positive (including 141 patients with EGFR sensitive mutations) were enrolled to analyze the relationship between clinicopathological characteristics and PD-L1 expression. The factors affecting the therapeutic effect of EGFR-TKIs in 141 patients with EGFR sensitive mutations were also explored. Results: The PD-L1 expression of the included patients was classified according to the tumor promotion score (TPS): negative (TPS<1%) accounted for 47.2%, low expression (1%≤TPS<50%) accounted for 32.1%, and high expression (TPS≥50%) accounted for 20.7%. Among them, patients with solid predominant cancer cell pathomorphology classification are more likely to have high expression of PD-L1, accounting for 52.9% (P<0.0001). The median progression-free survival (mPFS) of patients with PD-L1 negative expression, low expression and high expression who received first generation EGFR-TKIs treatment were 12.4 months, 10.5 months and 3.7 months, respectively, with significant statistical difference (P<0.0001). During the EGFR-TKIs treatment, patients with a history of radiotherapy for lung lesions have a longer PFS benefit than those without a history of radiotherapy (mPFS: 17.0 months vs 9.3 months, P<0.0001). Conclusions: The expression level of PD-L1 in advanced EGFR positive NSCLC patients was significantly correlated with the pathomorphology classification of cancer cells. The efficacy of EGFR-TKIs in patients with PD-L1 overexpression NSCLC was significantly poor. PFS can be significantly prolonged during targeted therapy combined with radiotherapy of lung lesions.

Expression of EGFR in locally advanced oral squamous carcinoma and its relationship with TPF induction chemotherapy

TPF Induction Chemotherapy and Pathologic Response for Patients with Locally Advanced and Resectable Oral Squamous Cell Carcinoma.

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Expression of P-EGFR and P-Akt Protein in Esophageal Squamous Cell Carcinoma and Its Prognosis

Elevated Growth Differentiating Factor 15 Expression Predicts Long-Term Benefit of Docetaxel, Cisplatin and 5-Fluorouracil Induction Chemotherapy in Patients with Oral Cancer

Mechanism of Sensitivity to TPF Chemoagents and Its Potential Alternative of Erbb2 in Oral Cancer with GDF15 Overexpression.

GDF15 is a Potential Predictive Biomarker for TPF Induction Chemotherapy and Promotes Tumorigenesis and Progression in Oral Squamous Cell Carcinoma

Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer

[Correlation Between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].

[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs]

Neoadjuvant Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma: A Single Center Study

The Expression of EGFR by Immunohistochemical Staining to Predict the Response of Nimotuzumab in Esophageal Squamous Cell Carcinoma.

An Evaluation Of Phosphorylated Egfr Expression In Predicting Outcome Of Egfr-Tki Therapy For The Advanced Nsclc Patients With Egfr Wild Type.

The Relationship Between Preliminary Efficacy and Prognosis after First-Line EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment of Advanced Non-Small Cell Lung Cancer

[Analysis for Potential Targeting Genes of TPF Regimen Induction Chemotherapy in Hypopharyngeal Squamous Cell Carcinoma].

Clinical significance of EGFR and EGFRvIII expression in human esophageal carcinoma

Expression of Megfr, Pegfr(Thr654), and Ppkn1(Thr774) to Predict Response to Chemoradiation and Prognosis in Patients with Cervical Cancer.

Protein Overexpression and Gene Amplification of EGFR in Esophageal Squamous Cell Carcinoma: Relationship Between Malignant Biologic Behavior and EGFR Status Study.

EGFR-Mutated Squamous Cell Lung Cancer and Its Association with Outcomes.